This suggests that a subgroup of CRIPTO-expressing HCC patients may benefit from a combinatorial treatment scheme and that sorafenib resistance may be circumventable by inhibition of GRP78 [96]. Here, HSPA5 is linked to hepatocellular carcinoma.